The many faces of the SOCS box

Cytokine and Growth Factor Reviews

Volumn 19, Issue 5-6, 2008, Pages 371-381

  Piessevaux, Julie ^a   Lavens, Delphine ^a   Peelman, Frank ^a   Tavernier, Jan ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Cytokine receptor; E3 ligase; Signal transduction; SOCS; SOCS box

Indexed keywords

BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CYTOKINE; PROTEIN SH2; SOCS BOX PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 57049091056     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2008.08.006     Document Type: Review

References (125)

1. Greenhalgh C.J., and Hilton D.J. Negative regulation of cytokine signaling. J Leukoc Biol 70 3 (2001) 348-356
2. Wormald S., and Hilton D.J. Inhibitors of cytokine signal transduction. J Biol Chem 279 2 (2004) 821-824
3. Yoshimura A., Ohkubo T., Kiguchi T., Jenkins N.A., Gilbert D.J., Copeland N.G., et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J 14 12 (1995) 2816-2826
4. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 6636 (1997) 921-924
5. Krebs D.L., and Hilton D.J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19 5 (2001) 378-387
6. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 6 (2003) 540-545
7. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4 6 (2003) 546-550
8. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4 6 (2003) 551-556
9. Fujimoto M., and Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24 12 (2003) 659-666
10. Johnston J.A. Are SOCS suppressors, regulators, and degraders?. J Leukoc Biol 75 5 (2004) 743-748
11. Yoshimura A., Naka T., and Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7 6 (2007) 454-465
12. O'Shea J.J., and Murray P.J. Cytokine signaling modules in inflammatory responses. Immunity 28 4 (2008) 477-487
13. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18 5 (1999) 1309-1320
14. Babon J.J., McManus E.J., Yao S., DeSouza D.P., Mielke L.A., Sprigg N.S., et al. The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol Cell 22 2 (2006) 205-216
15. Bullock A.N., Rodriguez M.C., Debreczeni J.E., Songyang Z., and Knapp S. Structure of the SOCS4-Elongin B/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 15 11 (2007) 1493-1504
16. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4 6 (1999) 339-351
17. Giordanetto F., and Kroemer R.T. A three-dimensional model of suppressor of cytokine signalling 1 (SOCS-1). Protein Eng 16 2 (2003) 115-124
18. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97 12 (2000) 6493-6498
19. Ram P.A., and Waxman D.J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 274 50 (1999) 35553-35561
20. Callus B.A., and Mathey-Prevot B. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 91 9 (1998) 3182-3192
21. Verdier F., Chretien S., Muller O., Varlet P., Yoshimura A., Gisselbrecht S., et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem 273 43 (1998) 28185-28190
22. Landsman T., and Waxman D.J. Role of the cytokine-induced SH2-containing protein CIS in growth hormone receptor internalization. J Biol Chem (2005)
23. Irandoust M.I., Aarts L.H., Roovers O., Gits J., Erkeland S.J., and Touw I.P. Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J 26 11 (2007) 2822
24. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97 19 (2000) 10430-10435
25. Kile B.T., Schulman B.A., Alexander W.S., Nicola N.A., Martin H.M., and Hilton D.J. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 27 5 (2002) 235-241
26. Kibel A., Iliopoulos O., DeCaprio J.A., and Kaelin Jr. W.G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 5229 (1995) 1444-1446
27. Aso T., Haque D., Barstead R.J., Conaway R.C., and Conaway J.W. The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex. EMBO J 15 20 (1996) 5557-5566
28. Kamura T., Sato S., Haque D., Liu L., Kaelin Jr. W.G., Conaway R.C., et al. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12 24 (1998) 3872-3881
29. Zhang J.G., Farley A., Nicholson S.E., Willson T.A., Zugaro L.M., Simpson R.J., et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to Elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 96 5 (1999) 2071-2076
30. Kamura T., Maenaka K., Kotoshiba S., Matsumoto M., Kohda D., Conaway R.C., et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 18 24 (2004) 3055-3065
31. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 96 22 (1999) 12436-12441
32. Kamura T., Burian D., Yan Q., Schmidt S.L., Lane W.S., Querido E., et al. Muf1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase. J Biol Chem 276 32 (2001) 29748-29753
33. Kamizono S., Hanada T., Yasukawa H., Minoguchi S., Kato R., Minoguchi M., et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 276 16 (2001) 12530-12538
34. Frantsve J., Schwaller J., Sternberg D.W., Kutok J., and Gilliland D.G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21 10 (2001) 3547-3557
35. Ungureanu D., Saharinen P., Junttila I., Hilton D.J., and Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 22 10 (2002) 3316-3326
36. Orr S.J., Morgan N.M., Buick R.J., Boyd C.R., Elliott J., Burrows J.F., et al. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem 282 6 (2007) 3418-3422
37. Orr S.J., Morgan N.M., Elliott J., Burrows J.F., Scott C.J., McVicar D.W., et al. CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood 109 3 (2007) 1061-1068
38. De Sepulveda P., Ilangumaran S., and Rottapel R. Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. J Biol Chem 275 19 (2000) 14005-14008
39. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y.C., Wulf G., et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12 6 (2003) 1413-1426
40. Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J., et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 7 2 (2006) 148-155
41. Kamio M., Yoshida T., Ogata H., Douchi T., Nagata Y., Inoue M., et al. SOCS1 [corrected] inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. Oncogene 23 17 (2004) 3107-3115
42. Rui L., Yuan M., Frantz D., Shoelson S., and White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277 44 (2002) 42394-42398
43. Liu E., Cote J.F., and Vuori K. Negative regulation of FAK signaling by SOCS proteins. EMBO J 22 19 (2003) 5036-5046
44. Zhang J.G., Metcalf D., Rakar S., Asimakis M., Greenhalgh C.J., Willson T.A., et al. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc Natl Acad Sci USA 98 23 (2001) 13261-13265
45. Boyle K., Egan P., Rakar S., Willson T.A., Wicks I.P., Metcalf D., et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood (2007)
46. Ram P.A., and Waxman D.J. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 275 50 (2000) 39487-39496
47. Greenhalgh C.J., Rico-Bautista E., Lorentzon M., Thaus A.L., Morgan P.O., Willson T.A., et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115 2 (2005) 397-406
48. Kario E., Marmor M.D., Adamsky K., Citri A., Amit I., Amariglio N., et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 280 8 (2005) 7038-7048
49. Nicholson S.E., Metcalf D., Sprigg N.S., Columbus R., Walker F., Silva A., et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signalling. Proc Natl Acad Sci USA 102 7 (2005) 2328-2333
50. Bayle J., Lopez S., Iwai K., Dubreuil P., and De Sepulveda P. The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett 580 11 (2006) 2609-2614
51. Chen X.P., Losman J.A., Cowan S., Donahue E., Fay S., Vuong B.Q., et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 99 4 (2002) 2175-2180
52. Limnander A., Danial N.N., and Rothman P.B. v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. Mol Cell 15 3 (2004) 329-341
53. Sasaki A., Inagaki-Ohara K., Yoshida T., Yamanaka A., Sasaki M., Yasukawa H., et al. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J Biol Chem 278 4 (2003) 2432-2436
54. Narazaki M., Fujimoto M., Matsumoto T., Morita Y., Saito H., Kajita T., et al. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci USA 95 22 (1998) 13130-13134
55. Hanada T., Yoshida T., Kinjyo I., Minoguchi S., Yasukawa H., Kato S., et al. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box. J Biol Chem 276 44 (2001) 40746-40754
56. Haan S., Ferguson P., Sommer U., Hiremath M., McVicar D.W., Heinrich P.C., et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem 278 34 (2003) 31972-31979
57. Piessevaux J., De Ceuninck L., Catteeuw D., Peelman F., and Tavernier J. Elongin B/C recruitment regulates substrate binding by CIS. J Biol Chem (2008)
58. Feldman D.E., Thulasiraman V., Ferreyra R.G., and Frydman J. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell 4 6 (1999) 1051-1061
59. Melville M.W., McClellan A.J., Meyer A.S., Darveau A., and Frydman J. The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol 23 9 (2003) 3141-3151
60. Kamura T., Brower C.S., Conaway R.C., and Conaway J.W. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 277 33 (2002) 30388-30393
61. Favre H., Benhamou A., Finidori J., Kelly P.A., and Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 453 1/2 (1999) 63-66
62. Greenhalgh C.J., Metcalf D., Thaus A.L., Corbin J.E., Uren R., Morgan P.O., et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 277 43 (2002) 40181-40184
63. Metcalf D., Greenhalgh C.J., Viney E., Willson T.A., Starr R., Nicola N.A., et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405 6790 (2000) 1069-1073
64. Tannahill G.M., Elliott J., Barry A.C., Hibbert L., Cacalano N.A., and Johnston J.A. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 25 20 (2005) 9115-9126
65. Piessevaux J., Lavens D., Montoye T., Wauman J., Catteeuw D., Vandekerckhove J., et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 281 44 (2006) 32953-32966
66. Pezet A., Favre H., Kelly P.A., and Edery M. Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem 274 35 (1999) 24497-24502
67. Dif F., Saunier E., Demeneix B., Kelly P.A., and Edery M. Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor. Endocrinology 142 12 (2001) 5286-5293
68. Lavens D., Montoye T., Piessevaux J., Zabeau L., Vandekerckhove J., Gevaert K., et al. A complex interaction pattern of CIS and SOCS2 with the leptin receptor. J Cell Sci 119 Pt 11 (2006) 2214-2224
69. Ouyang X., Fujimoto M., Nakagawa R., Serada S., Tanaka T., Nomura S., et al. SOCS-2 interferes with myotube formation and potentiates osteoblast differentiation through upregulation of JunB in C2C12 cells. J Cell Physiol 207 2 (2006) 428-436
70. Wu K.L., Miao H., and Khan S. JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated. HIF-independent mechanism. Am J Physiol Renal Physiol (2007)
71. Zheng C., Li L., Haak M., Brors B., Frank O., Giehl M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 6 (2006) 1028-1034
72. Schultheis B., Carapeti-Marootian M., Hochhaus A., Weisser A., Goldman J.M., and Melo J.V. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99 5 (2002) 1766-1775
73. Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., and Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102 2 (2003) 630-637
74. Li L., Gronning L.M., Anderson P.O., Li S., Edvardsen K., Johnston J., et al. Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem 279 33 (2004) 34107-34114
75. Liu X., Mameza M.G., Lee Y., Eseonu C.I., Yu C.R., Kang Derwent J.J., et al. Suppressors of cytokine signaling (SOCS) proteins induce insulin-resistance in the retina and promote survival of retinal cells. Diabetes (2008)
76. Rawlings J.S., Rennebeck G., Harrison S.M., Xi R., and Harrison D.A. Two Drosophila suppressors of cytokine signaling (SOCS) differentially regulate JAK and EGFR pathway activities. BMC Cell Biol 5 1 (2004) 38
77. Brender C., Nielsen M., Ropke C., Nissen M.H., Svejgaard A., Billestrup N., et al. Interferon-alpha induces transient suppressors of cytokine signalling expression in human T cells. Exp Clin Immunogenet 18 2 (2001) 80-85
78. Adams T.E., Hansen J.A., Starr R., Nicola N.A., Hilton D.J., and Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 273 3 (1998) 1285-1287
79. Toniato E., Chen X.P., Losman J., Flati V., Donahue L., and Rothman P. TRIM8/GERP RING finger protein interacts with SOCS-1. J Biol Chem 277 40 (2002) 37315-37322
80. Peraldi P., Filloux C., Emanuelli B., Hilton D.J., and Van Obberghen E. Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem 276 27 (2001) 24614-24620
81. Sommer U., Schmid C., Sobota R.M., Lehmann U., Stevenson N.J., Johnston J.A., et al. Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem 280 36 (2005) 31478-31488
82. Cacalano N.A., Sanden D., and Johnston J.A. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates. Ras Nat Cell Biol 3 5 (2001) 460-465
83. Sitko J.C., Guevara C.I., and Cacalano N.A. Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation. J Biol Chem 279 36 (2004) 37662-37669
84. Li S., Chen S., Xu X., Sundstedt A., Paulsson K.M., Anderson P., et al. Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells. J Exp Med 191 6 (2000) 985-994
85. Lavens D., Ulrichts P., Catteeuw D., Gevaert K., Vandekerckhove J., Peelman F., et al. The C-terminus of CIS defines its interaction pattern. Biochem J 401 1 (2007) 257-267
86. Uyttendaele I., Lemmens I., Verhee A., De Smet A.S., Vandekerckhove J., Lavens D., et al. MAPPIT analysis of STAT5, CIS and SOCS2 interactions with the growth hormone receptor. Mol Endocrinol 21 11 (2007) 2821-2831
87. Aman M.J., Migone T.S., Sasaki A., Ascherman D.P., Zhu M., Soldaini E., et al. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling. J Biol Chem 274 42 (1999) 30266-30272
88. Matsumoto A., Seki Y., Kubo M., Ohtsuka S., Suzuki A., Hayashi I., et al. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19 9 (1999) 6396-6407
89. Stebbins C.E., Kaelin Jr. W.G., and Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284 5413 (1999) 455-461
90. Bullock A.N., Debreczeni J.E., Edwards A.M., Sundstrom M., and Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci USA 103 20 (2006) 7637-7642
91. Lewis M.D., and Roberts B.J. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. Oncogene 23 13 (2004) 2315-2323
92. Zimmermann S., Murray P.J., Heeg K., and Dalpke A.H. Induction of suppressor of cytokine signaling-1 by Toxoplasma gondii contributes to immune evasion in macrophages by blocking IFN-gamma signaling. J Immunol 176 3 (2006) 1840-1847
93. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98 5 (1999) 597-608
94. Stoiber D., Stockinger S., Steinlein P., Kovarik J., and Decker T. Listeria monocytogenes modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. J Immunol 166 1 (2001) 466-472
95. Moutsopoulos N.M., Vazquez N., Greenwell-Wild T., Ecevit I., Horn J., Orenstein J., et al. Regulation of the tonsil cytokine milieu favors HIV susceptibility. J Leukoc Biol 80 5 (2006) 1145-1155
96. Isomaki P., Alanara T., Isohanni P., Lagerstedt A., Korpela M., Moilanen T., et al. The expression of SOCS is altered in rheumatoid arthritis. Rheumatology (Oxford) 46 10 (2007) 1538-1546
97. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193 4 (2001) 471-481
98. Rakoff-Nahoum S., Hao L., and Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25 2 (2006) 319-329
99. Lovato P., Brender C., Agnholt J., Kelsen J., Kaltoft K., Svejgaard A., et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 278 19 (2003) 16777-16781
100. Egan P.J., Lawlor K.E., Alexander W.S., and Wicks I.P. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 111 6 (2003) 915-924
101. Bjorbaek C., Elmquist J.K., Frantz J.D., Shoelson S.E., and Flier J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1 4 (1998) 619-625
102. Howard J.K., Cave B.J., Oksanen L.J., Tzameli I., Bjorbaek C., and Flier J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10 7 (2004) 734-738
103. Mori H., Hanada R., Hanada T., Aki D., Mashima R., Nishinakamura H., et al. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 10 7 (2004) 739-743
104. Dunn S.L., Bjornholm M., Bates S.H., Chen Z., Seifert M., and Myers Jr. M.G. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol Endocrinol 19 4 (2005) 925-938
105. Emanuelli B., Peraldi P., Filloux C., Sawka-Verhelle D., Hilton D., and Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275 21 (2000) 15985-15991
106. Kawazoe Y., Naka T., Fujimoto M., Kohzaki H., Morita Y., Narazaki M., et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 193 2 (2001) 263-269
107. Emanuelli B., Peraldi P., Filloux C., Chavey C., Freidinger K., Hilton D.J., et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276 51 (2001) 47944-47949
108. Ueki K., Kondo T., and Kahn C.R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24 12 (2004) 5434-5446
109. Ueki K., Kadowaki T., and Kahn C.R. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 33 2 (2005) 185-192
110. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17 3 (2003) 488-490
111. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Cervantes F., Barrios M., Colomer D., et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 89 1 (2004) 42-48
112. Sakai I., Takeuchi K., Yamauchi H., Narumi H., and Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100 8 (2002) 2926-2931
113. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100 24 (2003) 14133-14138
114. Komazaki T., Nagai H., Emi M., Terada Y., Yabe A., Jin E., et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34 4 (2004) 191-194
115. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 1 (2001) 29-35
116. Nagai H., Naka T., Terada Y., Komazaki T., Yabe A., Jin E., et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 48 2 (2003) 65-69
117. Wikman H., Kettunen E., Seppanen J.K., Karjalainen A., Hollmen J., Anttila S., et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 21 37 (2002) 5804-5813
118. Farabegoli F., Ceccarelli C., Santini D., and Taffurelli M. Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol 58 10 (2005) 1046-1050
119. Watanabe D., Ezoe S., Fujimoto M., Kimura A., Saito Y., Nagai H., et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126 5 (2004) 726-735
120. Galm O., Yoshikawa H., Esteller M., Osieka R., and Herman J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101 7 (2003) 2784-2788
121. Raccurt M., Tam S.P., Lau P., Mertani H.C., Lambert A., Garcia-Caballero T., et al. Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89 3 (2003) 524-532
122. Evans M.K., Yu C.R., Lohani A., Mahdi R.M., Liu X., Trzeciak A.R., et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 26 13 (2007) 1941-1948
123. Haffner M.C., Petridou B., Peyrat J.P., Revillion F., Muller-Holzner E., Daxenbichler G., et al. Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer 7 (2007) 136
124. Komyod W., Bohm M., Metze D., Heinrich P.C., and Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 5 3 (2007) 271-281
125. Babon J.J., Sabo J.K., Soetopo A., Yao S., Bailey M.F., Zhang J.G., et al. The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol 381 (2008) 928-940